Understanding the
Unmet Need
Major Safety and
Tolerability Challenges Unnecessary Exposure to
Extended Endocrine Therapy Side Effects Lead
to Noncompliance
About Breast Cancer Index (BCI)
About BCI How is BCI Used? Predictive Studies Prognostic Studies Health Economics Study
Patient Scenarios Ordering Information Videos News & Press
bioTheranostics Privacy Statement Terms and Conditions Site Map

bioTheranostics, Inc.
9640 Towne Centre Drive | Suite 200
San Diego, CA 92121
bioTheranostics.com

US and International: +1 (858) 587-5870
Fax: +1 (858) 587-5874
Client Services: +1 (877) 886-6739
Billing Information: +1 (858) 682-9279

© 2015 bioTheranostics, Inc.
Breast Cancer Index and BCI are service marks of bioTheranostics, Inc.

< Back

Tour the Test Report

Prognostic Score

  • 0 - 10
  • Individualized risk of late recurrence*

*If ordered at time of diagnosis, test report also provides overall (years 0-10), early (0-5 year), and late (5-10 year) risk of recurrence

Prognostic Study PROGNOSTIC STUDIES

Predictive Score

  • Predictive of likelihood of benefit from extended endocrine therapy
  • HIGH or LOW (binary result)
Predictive Study PREDICTIVE STUDIES

Health Economics Study

BCI: a cost-effective tool in the extended endocrine therapy setting1

BCI may provide cost savings in the extended treatment setting

  • Use of BCI in patients with ER+, LN- early-stage breast cancer is cost saving compared with standard management*
  • BCI projected to yield a net cost savings of $1803 per patient tested (in the 5-year, post-diagnosis population)
  • Savings achieved through projected impact on extended endocrine therapy use and compliance
  • Savings driven by optimization of extended endocrine therapy utilization in patients likely to receive substantial benefit
  • These findings require validation in additional cohorts, including studies of real-world clinical practice

From a third-party payer perspective, use of BCI may result in substantially lower overall medical costs.

View Study
*Two fact-based economic models were developed to project the cost and effectiveness of BCI in a hypothetical population of patients with ER+, LN- breast cancer compared with standard clinicopathologic diagnostic modalities. The models examined cost utility compared with standard practice when used at diagnosis and in patients disease-free at 5 years post diagnosis. Results in the extended endocrine therapy setting are included here.
Order BCI

References

  1. Gustavesen G, et al. Am J Manag Care 2014;20:e302-e310

Breast Cancer Index Indications for Use and Limitations

BCI provides a quantitative assessment of the likelihood of distant recurrence in patients diagnosed with ER+ node-negative breast cancer, and prediction of likelihood of benefit from extended (>5 year) endocrine therapy in patients who are recurrence-free after an initial 5 years of adjuvant endocrine therapy. Treatment decisions require correlation with all other clinical findings. This test was developed and its performance characteristics determined by bioTheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. bioTheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high-complexity clinical laboratory testing.